𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Analysis of Court Criteria for Awarding Disability Benefits to Patients With Crohn's Disease

✍ Scribed by Calvet, Xavier; Motos, Jaime; Montserrat, Antònia; Gallardo, Olga; Vergara, Mercedes


Book ID
123138964
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
234 KB
Volume
7
Category
Article
ISSN
1542-3565

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Risk–benefit analysis of adalimumab vers
✍ Edward V. Loftus Jr; Scott J. Johnson; Si-Tien Wang; Eric Wu; Parvez M. Mulani; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 474 KB 👁 1 views

Background: Adalimumab is indicated for the treatment of moderately to severely active Crohn's disease (CD). A systematic analysis of risks and benefits of adalimumab versus traditional non-biologic therapies for patients refractory to non-biologic therapy is lacking. Methods: A base-case analysis